NKTR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NKTR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Nektar Therapeutics's current share price is $1.32. Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.96. Nektar Therapeutics's Cyclically Adjusted PS Ratio for today is 0.67.
The historical rank and industry rank for Nektar Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Nektar Therapeutics's highest Cyclically Adjusted PS Ratio was 81.46. The lowest was 0.23. And the median was 8.77.
NKTR's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Nektar Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.125. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.96 for the trailing ten years ended in Dec. 2023.
The historical data trend for Nektar Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 1.12 | 0.35 | 0.28 | 0.30 | 0.29 |
For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Nektar Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 1.32 | / | 1.96 | |
= | 0.67 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Nektar Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.125 | / | 129.4194 | * | 129.4194 | |
= | 0.125 |
Current CPI (Dec. 2023) = 129.4194.
Nektar Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201403 | 0.160 | 99.695 | 0.208 |
201406 | 0.224 | 100.560 | 0.288 |
201409 | 1.005 | 100.428 | 1.295 |
201412 | 0.151 | 99.070 | 0.197 |
201503 | 0.802 | 99.621 | 1.042 |
201506 | 0.172 | 100.684 | 0.221 |
201509 | 0.452 | 100.392 | 0.583 |
201512 | 0.293 | 99.792 | 0.380 |
201603 | 0.434 | 100.470 | 0.559 |
201606 | 0.240 | 101.688 | 0.305 |
201609 | 0.265 | 101.861 | 0.337 |
201612 | 0.251 | 101.863 | 0.319 |
201703 | 0.161 | 102.862 | 0.203 |
201706 | 0.223 | 103.349 | 0.279 |
201709 | 0.940 | 104.136 | 1.168 |
201712 | 0.603 | 104.011 | 0.750 |
201803 | 0.236 | 105.290 | 0.290 |
201806 | 5.967 | 106.317 | 7.264 |
201809 | 0.161 | 106.507 | 0.196 |
201812 | 0.219 | 105.998 | 0.267 |
201903 | 0.162 | 107.251 | 0.195 |
201906 | 0.134 | 108.070 | 0.160 |
201909 | 0.167 | 108.329 | 0.200 |
201912 | 0.192 | 108.420 | 0.229 |
202003 | 0.285 | 108.902 | 0.339 |
202006 | 0.274 | 108.767 | 0.326 |
202009 | 0.168 | 109.815 | 0.198 |
202012 | 0.131 | 109.897 | 0.154 |
202103 | 0.130 | 111.754 | 0.151 |
202106 | 0.155 | 114.631 | 0.175 |
202109 | 0.135 | 115.734 | 0.151 |
202112 | 0.135 | 117.630 | 0.149 |
202203 | 0.134 | 121.301 | 0.143 |
202206 | 0.116 | 125.017 | 0.120 |
202209 | 0.126 | 125.227 | 0.130 |
202212 | 0.117 | 125.222 | 0.121 |
202303 | 0.114 | 127.348 | 0.116 |
202306 | 0.108 | 128.729 | 0.109 |
202309 | 0.127 | 129.860 | 0.127 |
202312 | 0.125 | 129.419 | 0.125 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Howard W Robin | director, officer: President & CEO | |
Jonathan Zalevsky | officer: Chief R&D Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Mark Andrew Wilson | officer: SVP & General Counsel | 1613 RAY DRIVE, BURLINGAME CA 94010 |
Myriam Curet | director | 1020 KIFER ROAD, SUNNYVALE CA 94086 |
Jeffrey Robert Ajer | director | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Sandra A. Gardiner | officer: Chief Financial Officer | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Jillian B. Thomsen | officer: VP & Chief Accounting Officer | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Robert Chess | director, officer: Executive Chairman | |
Karin Eastham | director | C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
Gil M Labrucherie | officer: SVP, COO & CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
John Northcott | officer: SVP & Chief Commercial Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Diana Brainard | director | C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
R Scott Greer | director | 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253 |
Lutz Lingnau | director | 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945 |
Stephen K Doberstein | officer: Chief Scientific Officer | 129 ELSIE STREET, SAN FRANCISCO CA 94110 |
From GuruFocus
By PRNewswire • 09-13-2023
By Business Wire Business Wire • 02-01-2023
By PRNewswire PRNewswire • 11-09-2022
By PRNewswire PRNewswire • 01-04-2023
By PRNewswire PRNewswire • 12-05-2022
By PRNewswire • 09-06-2023
By PRNewswire • 10-02-2023
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire • 10-13-2023
By PRNewswire PRNewswire • 06-12-2023